Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events

References

• NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 1.2015. Fort Washington, PA: National Comprehensive Cancer Network, 2015. Available from: www.nccn.org/professionals/physician_gls/pdf/cml.pdf [Last accessed 31 March 2015]
   Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30:3486-92
   PubMed Web of Science ®Google Scholar
• Lipton JH, Chuah C, Guerci-Bresler A, et al. EPIC: A Phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML). Blood 2014;124:abstract 519
   Web of Science ®Google Scholar
• Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:abstract 1126
   Web of Science ®Google Scholar
• Guerin A, Chen L, Ionescu-Ittu R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin 2014;30:2317-28
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8
   PubMed Web of Science ®Google Scholar
• Giles FJ, O’Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009;23:1698-707
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Cervantes F, le Coutre P, et al. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 2012;53:2351-61
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Gleevec (imatinib) [package insert]. Novartis Pharmaceuticals Corp, East Hanover, NJ; 2014
   Google Scholar
• Tasigna (nilotinib) [package insert]. Novartis Pharmaceuticals Corp, East Hanover, NJ; 2014
   Google Scholar
• Sprycel (dasatinib) [package insert]. Bristol-Myers Squibb Co, Princeton, NJ; 2014
   Google Scholar
• Bosulif (bosutinib) [package insert]. Pfizer Inc., New York, NY; 2013
   Google Scholar
• Iclusig (ponatinib) [package insert]. ARIAD Pharmaceuticals, Inc, Cambridge, MA; 2014
   Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841-51
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-203
   PubMed Web of Science ®Google Scholar
• Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014;123:1353-60
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-9
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500
   PubMed Web of Science ®Google Scholar
• Cortes J, Hochhaus A, Kim D-W, et al. Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response. Blood 2013;122:abstract 653
   Web of Science ®Google Scholar
• Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014;89:947-53
   PubMed Web of Science ®Google Scholar
• Brummendorf TH, Cortes JE, de Souza CA, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 2015;168:69-81
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: FDA investigating leukemia drug Iclusig (ponatinib) after increased reports of serious blood clots in arteries and veins. Silver Spring, MD: US Food and Drug Administration, 2013. Available from: www.fda.gov/Drugs/DrugSafety/ucm370945.htm [Last accessed 22 January 2015]
   Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141-5
   PubMed Web of Science ®Google Scholar
• Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27:107-12
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim DW, Kantarjian H, et al.Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232-40
   PubMed Web of Science ®Google Scholar
• Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 2014;123:2317-24
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118:4567-76
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Brummendorf TH, Kim DW, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol 2014;89:732-42
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783-96
   PubMed Web of Science ®Google Scholar
• Futosi K, Nemeth T, Pick R, et al. Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood 2012;119:4981-91
   PubMed Web of Science ®Google Scholar
• Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008;49:615-19
   PubMed Web of Science ®Google Scholar
• Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23:477-85
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-12
   PubMed Web of Science ®Google Scholar
• Gauld SB, Cambier JC. Src-family kinases in B-cell development and signaling. Oncogene 2004;23:8001-6
   PubMed Web of Science ®Google Scholar
• Zhu HH, Ji K, Alderson N, et al. Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool. Blood 2011;117:5350-61
   PubMed Web of Science ®Google Scholar
• Rea D, Gautier J, Breccia M, et al. Incidence of hyperglycemia by 3 years in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib (NIL) or imatinib (IM) in ENESTnd. Blood 2012;120:abstract 1686
   Web of Science ®Google Scholar
• Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica 2014;99:1197-203
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Long-term follow-up of ponatinib efficacy and safety in the Phase 2 PACE Trial. Blood 2014;124:abstract 3135
   Web of Science ®Google Scholar
• Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 2008;105:18895-900
   PubMed Web of Science ®Google Scholar
• Fitter S, Vandyke K, Schultz CG, et al. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 2010;95:3763-7
   PubMed Web of Science ®Google Scholar
• Breccia M, Muscaritoli M, Aversa Z, et al. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 2004;22:4653-5
   PubMed Web of Science ®Google Scholar
• Racil Z, Razga F, Drapalova J, et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica 2013;98:e124-6
   PubMed Web of Science ®Google Scholar
• Breccia M, Loglisci G, Salaroli A, et al. Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. Leuk Res 2012;36:e66-7
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1-45
   PubMed Web of Science ®Google Scholar
• Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S76-99
   PubMed Web of Science ®Google Scholar
• Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-6
   PubMed Web of Science ®Google Scholar
• Verma R, Vasudevan B, Pragasam V, et al. A rare case of imatinib-induced erythroderma. Indian J Pharmacol 2013;45:634-5
   PubMed Web of Science ®Google Scholar
• Bois E, Holle LM, Farooq U. Late onset imatinib-induced Stevens-Johnson syndrome. J Oncol Pharm Pract 2014;20:476-8
   PubMed Web of Science ®Google Scholar
• Arshdeep De D, Malhotra P, et al. Imatinib mesylate-induced severe lichenoid rash. Indian J Dermatol Venereol Leprol 2014;80:93-5
   PubMed Web of Science ®Google Scholar
• Kumar M, Mandal PK, Dolai TK, et al. Imatinib causing drug rash with eosinophilia and systemic symptoms: A rare cutaneous reaction. Indian Dermatol Online J 2014;5:S120-2
   Google Scholar
• Arora B, Kumar L, Sharma A, et al. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004;15:358-9
   PubMed Web of Science ®Google Scholar
• Grichnik JM, Burch JA, Burchette J, et al. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998;111:233-8
   PubMed Web of Science ®Google Scholar
• Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-34
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Baccarani M, et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) Trial (DASISION, CA180-056). Blood 2014;124:abstract 152
   Google Scholar
• Saglio G, le Coutre P, Cortes J, et al. Safety and tolerability of dasatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL): pooled analysis of over 2400 patients. Haematologica 2014;99:abstract P884
   Web of Science ®Google Scholar
• Latagliata R, Breccia M, Fava C, et al. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol 2013;31:103-9
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14
   PubMed Web of Science ®Google Scholar
• Iriyama N, Fujisawa S, Hagihara M, et al. The incidence of pleural effusion on dasatinib treatment is associated with CD56 positive cell values one month after commencing dasatinib and achievement of an early molecular response in newly diagnosed chronic myeloid leukemia patients: results of a D-First Study. Blood 2014;124:abstract 3142
   Web of Science ®Google Scholar
• Hu G, Place AT, Minshall RD. Regulation of endothelial permeability by Src kinase signaling: vascular leakage versus transcellular transport of drugs and macromolecules. Chem Biol Interact 2008;171:177-89
   PubMed Web of Science ®Google Scholar
• Han J, Zhang G, Welch EJ, et al. A critical role for Lyn kinase in strengthening endothelial integrity and barrier function. Blood 2013;122:4140-9
   PubMed Web of Science ®Google Scholar
• Weis S, Cui J, Barnes L, et al. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004;167:223-9
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Han X, Kantarjian H, et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261-3
   PubMed Web of Science ®Google Scholar
• Mazharian A, Ghevaert C, Zhang L, et al. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood 2011;117:5198-206
   PubMed Web of Science ®Google Scholar
• Neelakantan P, Marin D, Laffan M, et al. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy. Haematologica 2012;97:1444
   PubMed Web of Science ®Google Scholar
• Prevost N, Woulfe D, Tanaka T, et al. Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred. Proc Natl Acad Sci USA 2002;99:9219-24
   PubMed Web of Science ®Google Scholar
• Hughes T, le Coutre P, Jootar S, et al. ENESTnd 5-year follow-up: continued benefit of frontline nilotinib (NIL) compared with imatinib (IM) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP). Haematologica 2014;99:abstract s677
   Web of Science ®Google Scholar
• Cortes J, Kantarjian H, Khoury H, et al. Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib. Haematologica 2014;99:abstract P900
   Web of Science ®Google Scholar
• Dahlén T, Edgren G, Höglund M, et al. Increased risk of cardiovascular events associated with TKI treatment in chronic phase chronic myeloid leukemia. data from Swedish population-based registries. Blood 2014;124:abstract 3134
   Google Scholar
• Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128-37
   PubMed Web of Science ®Google Scholar
• Dumitrescu D, Seck C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011;38:218-20
   PubMed Web of Science ®Google Scholar
• Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533-9
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Gagnieu M-C, Heiblig M, et al. Cardio-vascular events occurring on ponatinib in chronic phase chronic myeloid leukemia patients, preliminary analysis of a multicenter cohort. Blood 2013;122:abstract 4020
   Google Scholar
• Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013;27:1310-15
   PubMed Web of Science ®Google Scholar
• Larson RA, Kim D-W, Issaragrilsil S, et al. Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f/u) of ENESTnd. Blood 2014;124:abstract 4541
   Web of Science ®Google Scholar
• Gugliotta G, Castagnetti F, Breccia M, et al. Five-year outcome of 215 newly diagnosed chronic myeloid leukemia patients treated frontline with nilotinib-based regimens: a gimema CML working party analysis. Blood 2014;124:abstract 3141
   Web of Science ®Google Scholar
• Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013;27:1316-21
   PubMed Web of Science ®Google Scholar
• Hekmatjou H, Roboz GJ, Ritchie EK, et al. Arterial thrombotic complications are uncommon in patients without cardiovascular risk factors and occur at equivalent rates in Chronic Myeloid Leukemia (CML) patients treated with imatinib and nilotinib. Blood 2014;124:abstract 1811
   Web of Science ®Google Scholar
• Gambacorti-Passerini C, Kantarjian H, Khoury H, et al. Long-term assessment of cardiac toxicity in patients with Ph+ leukemias treated with bosutinib. Haematologica 2014;99:abstract P903
   Web of Science ®Google Scholar
• le Coutre P, Kim D, Pinilla-Ibarz J, et al. Ponatinib in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: longer-term follow-up of the PACE trial. Haematologica 2014;99:abstract P893
   Web of Science ®Google Scholar
• Chislock EM, Ring C, Pendergast AM. Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci U S A 2013;110:12432-7
   PubMed Web of Science ®Google Scholar
• Hasinoff BB. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol Appl Pharmacol 2010;244:190-5
   PubMed Web of Science ®Google Scholar
• Ellison GM, Vicinanza C, Smith AJ, et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell 2013;154:827-42
   PubMed Web of Science ®Google Scholar
• van Berlo JH, Kanisicak O, Maillet M, et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 2014;509:337-41
   PubMed Web of Science ®Google Scholar
• Franco C, Ahmad PJ, Hou G, et al. Increased cell and matrix accumulation during atherogenesis in mice with vessel wall-specific deletion of discoidin domain receptor 1. Circ Res 2010;106:1775-83
   PubMed Web of Science ®Google Scholar
• Day E, Waters B, Spiegel K, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008;599:44-53
   PubMed Web of Science ®Google Scholar
• Canning P, Tan L, Chu K, et al. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. J Mol Biol 2014;426:2457-70
   PubMed Web of Science ®Google Scholar
• Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;115:2108-18
   PubMed Web of Science ®Google Scholar
• Jeon YW, Lee S-E, Kim S-H, et al. Six-year follow-up of dasatinib-related Pulmonary Arterial Hypertension (PAH) for chronic myeloid leukemia in single center. Blood 2013;122: abstract 4017
   Google Scholar
• Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:81-8
   PubMed Web of Science ®Google Scholar
• Montani D, Perros F, Gambaryan N, et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184:116-23
   PubMed Web of Science ®Google Scholar
• Pullamsetti SS, Berghausen EM, Dabral S, et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 2012;32:1354-65
   PubMed Web of Science ®Google Scholar
• Breccia M, Molica M, Zacheo I, et al. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. Ann Hematol 2015;94:393-7
   PubMed Web of Science ®Google Scholar
• Muramatsu H, Takahashi Y, Sakaguchi H, et al. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era. Int J Hematol 2011;93:186-91
   PubMed Web of Science ®Google Scholar
• Ishiguro H, Yasuda Y, Hyodo H, et al. Growth and endocrine function in long-term adult survivors of childhood stem cell transplant. Clin Pediatr Endocrinol 2009;18:1-14
   PubMedGoogle Scholar
• Millot F, Guilhot J, Baruchel A, et al. Imatinib has a negative impact on growth in children with previously untreated chronic myeloid leukaemia (CML) in early chronic phase (CP): results of the French national study. Blood 2013;122:abstract 4001
   Google Scholar
• Giona F, Mariani S, Gnessi L, et al. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica 2013;98:e25-7
   Google Scholar
• Tauer JT, Nowasz C, Sedlacek P, et al. Impairment of longitudinal growth by Tyrosine Kinase Inhibitor (TKI) treatment - data from a large pediatric cohort with Chronic Myeloid Leukemia (CML). Blood 2014;124:abstract 522
   Web of Science ®Google Scholar
• Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008;111:2538-47
   PubMed Web of Science ®Google Scholar
• de la Fuente J, Baruchel A, Biondi A, et al. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol 2014;167:33-47
   PubMed Web of Science ®Google Scholar
• Millot F, Baruchel A, Guilhot J, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011;29:2827-32
   PubMed Web of Science ®Google Scholar
• Wayne AS, Macedo CR, Szczudlo T, et al. Nilotinib Treatment in Pediatric Patients (pts) with Philadelphia Chromosome- Positive (Ph+) Leukemia Refractory to Prior Tyrosine Kinase Inhibitor (TKI) therapy: results from nilotinib compassionate use program. Blood 2008;112:abstract 4264
   Google Scholar
• Zwaan CM, Rizzari C, Mechinaud F, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol 2013;31:2460-8
   PubMed Web of Science ®Google Scholar
• Open Label, Phase II study to evaluate efficacy and safety of oral nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. (Dialog). Available from: https://clinicaltrials.gov/ct2/show/NCT01844765
   Google Scholar
• A Phase II study of dasatinib in children and adolescents with newly diagnosed Chronic Phase CML or With Ph+ Leukemias resistant or intolerant to imatinib. Available from: https://clinicaltrials.gov/ct2/show/NCT00777036
   Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118:4554-60
   PubMed Web of Science ®Google Scholar
• Mahon F, Baccarani M, Mauro M, et al. Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath. J Clin Oncol 2014;32:abstract TPS7124
   Web of Science ®Google Scholar
• Mizuta S, Tsurumi H, Sawa M, et al. Management of adverse events associated with dasatinib during early periods of therapy in the treatment of chronic myeloid leukemia -a clinical report of daria-01 study. Blood 2014;124:4537
   Web of Science ®Google Scholar